Form 4: Corcept Therapeutics Director Exercises Options and Sells Shares While Receiving New Grant

A director at Corcept Therapeutics exercised stock options and sold an equivalent number of shares, while also receiving a new grant of stock options.

Summary

• Daniel N. Swisher Jr., a Director of Corcept Therapeutics Inc. (CORT), engaged in equity transactions on June 10, 2025.
• He exercised 2,200 stock options at an exercise price of $14.08 per share.
• Concurrently, he sold 2,200 shares of common stock at a price of $70.61 per share. This sale was executed pursuant to a Rule 10b5-1 trading plan adopted on August 1, 2024.
• Following these transactions, his direct beneficial ownership of common stock is 0 shares.
• Additionally, Mr. Swisher was granted 15,000 new stock options with an exercise price of $72.27 per share. These options will vest ratably in equal installments on each monthly anniversary of June 10, 2025, over a one-year period, subject to his continued service.
• After all reported transactions, Mr. Swisher beneficially owns 9,900 previously held stock options and the newly granted 15,000 stock options, totaling 24,900 derivative securities.

Sentiment

Score: 5

Explanation: The document reports a routine insider transaction involving the exercise and sale of stock options, coupled with a new option grant. This is a standard compensation and liquidity event for executives and does not inherently indicate a significant positive or negative shift in company fundamentals or outlook.

Positives

• The grant of 15,000 new stock options to Director Daniel N. Swisher Jr. indicates continued alignment of his interests with shareholders and reflects ongoing compensation for his service.
• The sale of shares was conducted under a pre-arranged Rule 10b5-1 plan, which suggests the transaction was not based on new material non-public information.

Negatives

• Director Daniel N. Swisher Jr. sold 2,200 shares of common stock, reducing his direct beneficial ownership of common stock to zero following the transaction.

Future Outlook

The newly granted stock options will vest ratably in equal installments on each monthly anniversary of June 10, 2025, over a one-year period, subject to the Reporting Person's continued service.

Industry Context

This Form 4 filing details a routine insider transaction, common across publicly traded companies, where an executive exercises stock options and sells shares, often for liquidity or tax purposes, while also receiving new equity compensation. Such transactions are standard practice in executive compensation structures within the pharmaceutical and biotechnology industries.

Corporate Governance

Stakeholder Impact

• Shareholders: The transaction is a routine insider compensation and liquidity event, not directly impacting the company's operational or financial performance. The sale of shares is offset by the grant of new options, maintaining insider alignment.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Continued monthly vesting of the 15,000 newly granted stock options over a one-year period, subject to the Director's continued service.

Key Dates

Recommendation

Keywords

Corcept Therapeutics, CORT, Form 4, insider trading, stock options, share sale, director, executive compensation, 10b5-1 plan